Literature DB >> 21166590

"Forgiving" a missed daily dose.

Thomas R Macgregor.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21166590      PMCID: PMC3068869          DOI: 10.1089/AID.2010.0273

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  5 in total

1.  Long-term outcomes of HIV-infected patients with <95% rates of adherence to nonnucleoside reverse-transcriptase inhibitors.

Authors:  Anucha Apisarnthanarak; Linda M Mundy
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

2.  Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.

Authors:  Bregt S Kappelhoff; Alwin D R Huitema; Frank van Leth; Patrick A Robinson; Thomas R MacGregor; Joep M A Lange; Jos H Beijnen
Journal:  HIV Clin Trials       Date:  2005 Sep-Oct

Review 3.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

4.  In vitro-in vivo correlation for nevirapine extended release tablets.

Authors:  Sreeraj Macha; Chan-Loi Yong; Todd Darrington; Mark S Davis; Thomas R MacGregor; Mark Castles; Steven L Krill
Journal:  Biopharm Drug Dispos       Date:  2009-12       Impact factor: 1.627

5.  Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract.

Authors:  Sreeraj Macha; Chan-Loi Yong; Thomas R MacGregor; Mark Castles; Anne-Marie Quinson; Nicolas Rouyrre; Ian Wilding
Journal:  J Clin Pharmacol       Date:  2009-09-30       Impact factor: 3.126

  5 in total
  1 in total

Review 1.  A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

Authors:  Michele W Tang; Phyllis J Kanki; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2012-03       Impact factor: 9.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.